Suxiao Jiuxin Pill
Phase 3Small molecule
Suxiao Jiuxin Pill is one of 18 small molecule programs targeting Randomized Controlled Trial. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Randomized Controlled Trial
#DrugCompanyPhaseTrials
1Carafate
AbbVieApproved
Xylocaine
MMEDRx USA, Inc.
Phase 3
Antibiotic
PfizerPhase 3
Aldactone
PfizerPhase 2
Zofran
NovartisPhase 2
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 3
Bone Marrow Aspirate Concentrate
MMassachusetts General Hospital
Phase 3
Takecab
PPhathom Pharmaceuticals, Inc.
Phase 2
Epidiolex
Jazz PharmaceuticalsPhase 1
Suxiao Jiuxin Pill
PPeking University First Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Suxiao Jiuxin Pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPeking University First Hospital